A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy

NCT00116909 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Recurrent or Metastatic Cancer of the Head and Neck
Must Have Failed First-Line Therapy

Interventions

DRUG: OSI 7904L

Sponsor

OSI Pharmaceuticals